Lyell Immunopharma (LYEL)
(Delayed Data from NSDQ)
$1.15 USD
+0.02 (1.77%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.19 +0.04 (3.48%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Lyell Immunopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 546 | 640 | 615 | 613 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 11 | 11 | 5 | 0 |
Total Current Assets | 555 | 651 | 626 | 618 | 0 |
Net Property & Equipment | 103 | 123 | 120 | 77 | 0 |
Investments & Advances | 49 | 115 | 331 | 163 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 4 | 3 | 0 |
Total Assets | 750 | 938 | 1,127 | 908 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 4 | 3 | 9 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 28 | 29 | 29 | 28 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 4 | 14 | 12 | 0 |
Total Current Liabilities | 35 | 37 | 47 | 49 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 80 | 89 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 4 | 5 | 1 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 1,011 | 0 |
Total Liabilities | 95 | 104 | 198 | 1,201 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,657 | 1,608 | 1,516 | 41 | 0 |
Retained Earnings | -1,002 | -767 | -584 | -334 | 0 |
Other Equity | 0 | -8 | -2 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 655 | 833 | 930 | -293 | 0 |
Total Liabilities & Shareholder's Equity | 750 | 938 | 1,127 | 908 | 0 |
Total Common Equity | 655 | 833 | 930 | -293 | 0 |
Shares Outstanding | 251.80 | 249.30 | 239.40 | NA | NA |
Book Value Per Share | 2.60 | 3.34 | 3.88 | 0.00 | 0.00 |
Fiscal Year End for Lyell Immunopharma, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 491 | 526 | 546 | 575 | 596 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 9 | 8 | 8 | 11 | 11 |
Total Current Assets | 500 | 534 | 555 | 587 | 606 |
Net Property & Equipment | 93 | 98 | 103 | 108 | 114 |
Investments & Advances | 19 | 19 | 49 | 55 | 69 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 5 | 5 | 5 | 5 |
Total Assets | 654 | 694 | 750 | 795 | 835 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 5 | 5 | 4 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 26 | 25 | 28 | 30 | 25 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 3 | 2 | 1 | 4 |
Total Current Liabilities | 31 | 32 | 35 | 35 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 4 | 4 | 4 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 88 | 91 | 95 | 97 | 99 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,675 | 1,666 | 1,657 | 1,648 | 1,638 |
Retained Earnings | -1,109 | -1,063 | -1,002 | -949 | -898 |
Other Equity | 0 | 0 | 0 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 567 | 603 | 655 | 698 | 737 |
Total Liabilities & Shareholder's Equity | 654 | 694 | 750 | 795 | 835 |
Total Common Equity | 567 | 603 | 655 | 698 | 737 |
Shares Outstanding | 254.90 | 254.90 | 251.80 | 251.00 | 247.80 |
Book Value Per Share | 2.22 | 2.37 | 2.60 | 2.78 | 2.97 |